Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
BIOCON: Key takeaways
While Biocon will participate in the generic atorvastatin API opportunity, it is unsure
whether simvastatin revenues will remain intact or lose share to generic atorvastatin.
Generic atorvastatin accounts for largest share out of its statins revenues (30% of sales
ex-Axicorp).
No more phase III trials will be conducted in India for 1N 105.
US$350 mn from the Pfizer deal will be accounted over next 4-5 years and does not entail
any payments liked to capex.
Syngene/Clinegene needs to report four quarters of sequential growth before Biocon can
think of listing the subsidiary.
Manpower ramp-up on BMS contract is underway, although running late. Target is to
ramp up number of scientists working on BMS to 400.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
BIOCON: Key takeaways
While Biocon will participate in the generic atorvastatin API opportunity, it is unsure
whether simvastatin revenues will remain intact or lose share to generic atorvastatin.
Generic atorvastatin accounts for largest share out of its statins revenues (30% of sales
ex-Axicorp).
No more phase III trials will be conducted in India for 1N 105.
US$350 mn from the Pfizer deal will be accounted over next 4-5 years and does not entail
any payments liked to capex.
Syngene/Clinegene needs to report four quarters of sequential growth before Biocon can
think of listing the subsidiary.
Manpower ramp-up on BMS contract is underway, although running late. Target is to
ramp up number of scientists working on BMS to 400.
No comments:
Post a Comment